Label Changes for:
Sprycel (dasatinib) Tablets
Changes have been made to the ADVERSE REACTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) –
(Clinical Trials section revised of the package insert to include information from interim follow-up analyses of data coming from the ongoing Phase 3 studies CA180034 (with a minimum of 5 years follow-up) and CA180056 (with a minimum of 3 years follow-up).